Page 8 - Fabia Kehren News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fabia kehren. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fabia Kehren Today - Breaking & Trending Today

Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™ (rosuvastatin)

Grünenthal closes deal with AstraZeneca for European rights to CRESTOR™ (rosuvastatin)
News provided by
Share this article
Share this article
AACHEN, Germany, Feb. 10, 2021 /PRNewswire/ Grünenthal today announced the successful completion of its acquisition of the European rights to CRESTOR™ (excluding Spain and the UK) for a total consideration of up to US$ 350 million. Cardiovascular diseases are among the most burdensome diseases in Europe
1, said Gabriel Baertschi, CEO Grünenthal. With CRESTOR™, we are proud to provide a meaningful therapy option to those patients. The completion of this acquisition is an important milestone for Grünenthal.
Under the terms of this agreement, Grünenthal has acquired the exclusive rights to market CRESTOR™ and its second brands in more than 30 European markets. Grünenthal will also take over bulk production and packaging for the defined markets by 2025. CRESTOR™ continues to generate significant rev ....

Nordrhein Westfalen , United States , United Kingdom , Fabia Kehren , Gabriel Baertschi , Grunenthal Group , Head External Communications Editorial Management , Latin America , Head External Communications , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , தலை வெளிப்புறம் தகவல்தொடர்புகள் தலையங்கம் மேலாண்மை , லத்தீன் அமெரிக்கா , தலை வெளிப்புறம் தகவல்தொடர்புகள் ,

Florian Dieckmann new VP Global Communications at Grünenthal

Florian Dieckmann new VP Global Communications at Grünenthal
AACHEN, Germany, Jan. 12, 2021 /PRNewswire/ Florian Dieckmann joined Grünenthal as the new Vice President and Head Global Communications on 1 January 2021. He succeeds Štepán Krácala, who transformed the research-driven pharmaceutical company s Communications department from 2018 until the end of last year. Florian Dieckmann now leads Grünenthal s communications activities across almost 30 markets worldwide, and manages the team at the company s headquarters in Aachen. He reports directly to CEO Gabriel Baertschi.
As a fully integrated pharmaceutical company, Grünenthal aims to further strengthen its research and innovation capacities in the field of pain therapy, and to tap into additional commercial growth opportunities in its core markets - particularly in Europe, the USA and Latin America. The company has completed several acquisitions and entered into a wide range of strategic partnerships in recent ....

Nordrhein Westfalen , United States , United Kingdom , Kostenloser Wertpapierhandel , Fabia Kehren , Prnewswire Florian Dieckmann , Gabriel Baertschi , Florian Dieckmann , Head Of Government Affairs , Grunenthal Group , Communications Department , Head External Communications Editorial Management , Head Global Communications , Communications For Latin America , Vice President , Government Affairs , Latin America , Eastern Europe , Middle East , Before Abbvie , Head External Communications , Gr 252 Nenthal , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , தலை ஆஃப் அரசு வாழ்க்கைத்தொழில்கள் ,

Peripheral NOP agonist addressing chronic peripheral neuropathic pain enters clinical development

Share:
AACHEN, Germany, Dec. 16, 2020 /PRNewswire/ Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of chronic peripheral neuropathic pain.
The Phase I trial will include 76 healthy participants. The trial aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound following single and multiple-ascending doses. The results of the study are expected to be available in 2021.
Pain remains a high unmet medical need that we strive to address with innovative medicines. Progressing our peripheral NOP agonist into clinical development is a major success in our efforts to build an industry-leading pipeline of investigational medicines, says Jan Adams, M.D., Chief Scientific Officer, Grünenth ....

Nordrhein Westfalen , United States , Fabia Kehren , Jan Adams , International Association For The Study Of Pain , Grunenthal Group , Trends In Pharmacological Sciences , Head External Communications Editorial Management , Chief Scientific Officer , International Association , Latin America , Head External Communications , Editorial Management , Rev Dis , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , ஒன்றுபட்டது மாநிலங்களில் , ஜான் ஆடம்ஸ் , சர்வதேச சங்கம் க்கு தி படிப்பு ஆஃப் வலி , போக்குகள் இல் மருந்தியல் அறிவியல் , தலை வெளிப்புறம் தகவல்தொடர்புகள் தலையங்கம் மேலாண்மை , தலைமை அறிவியல் அதிகாரி , சர்வதேச சங்கம் , லத்தீன் அமெரிக்கா , தலை வெளிப்புறம் தகவல்தொடர்புகள் , தலையங்கம் மேலாண்மை , ரெவ் திஸ் ,